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314 The Journal of Thoracic and CardioObjective: We report the preliminary results of a phase II trial undertaken to
determine the feasibility and efficacy of gemcitabine and concurrent radiotherapy in
patients with inoperable stage III non–small cell lung cancer.
Methods: Between February 2001 and June 2003, a total of 46 patients (37 male and
9 female, median age 64 years) with clinical stage III non–small cell lung cancer (41
cIIIA and 5 cIIIB) were enrolled in a combined chemoradiation protocol with
gemcitabine as the chemotherapeutic agent. Gemcitabine (350 mg/m2) was admin-
istered weekly for 5 consecutive weeks as a 30-minute intravenous infusion before
radiotherapy (total dose 50.4 Gy, 1.8 Gy/d). Toxicity was routinely assessed. Those
patients with disease judged to be resectable at restaging underwent surgery.
Results: Toxicity was moderate, with the exception of 1 grade 3 thrombocytopenia.
All but 5 patients were available for restaging. No complete responses were
observed. Thirty-four patients (82.9%) had partial responses, 5 (12.2%) had stable
disease, and 2 (4.9%) had progressive disease. Twenty-nine of 46 patients (63%, 27
cIIIA and 2 cIIIB) underwent surgery. Radical resection was possible in all cases.
Surgery included 17 lobectomies, 4 bilobectomies, and 8 pneumonectomies. There
were no deaths. Morbidity was 13.8% (4/29). Pathologic downstaging to stage 0 or
I was observed in 18 patients (39%, 18/46). After a median follow-up of 13 months
(range 2-28 months), 24 of the patients who had undergone operation (86.2%) were
alive, with a median disease-free survival of 16 months. Overall 2-year survival was
66.1%, with a significant difference between resected and unresected disease (82%
vs 36%, P  .0002).
Conclusion: The results of this induction trial confirm the feasibility and the efficacy
of gemcitabine with concurrent radiotherapy.
Lung cancer remains the number one cancerous cause of death among bothmen and women in developed countries. It was estimated that during 2004 inthe United States there would be about 173,770 new cases of lung cancer,
with an estimated 160,440 deaths.1 Despite years of research, the prognosis for
patients with lung cancer remains dismal, with a 5-year survival for all stages of
15%. Surgery remains the mainstay of therapy for early-stage lung cancer, achieving
5-year survivals of 70% for patients with stage I disease and 50% for those with
stage II.2 Unfortunately, most patients with lung cancer are first seen with advanced
(stage III) disease and are therefore less likely to benefit from surgery. Nor will they
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proaches (either radiotherapy or chemotherapy).
The treatment of stage III non–small cell lung cancer
(NSCLC) still remains challenging, with only complex mul-
timodality treatments playing a role in improving results.
Even if chemoradiotherapy is generally considered as the
standard of care for locally advanced disease,3 strategies
including neoadjuvant treatment followed by surgery have
shown good results, motivating researchers to explore this
approach.4
There is a growing body of data regarding the multimo-
dality neoadjuvant approach to locally advanced NSCLC.5-7
Although definitive conclusions cannot yet be drawn, sev-
eral phase II trials and some published randomized stud-
ies8-10 suggest that induction therapy is feasible, has insig-
nificant toxicity, and may improve long-term survival. Most
agents have been chosen for combination with radiotherapy
on the basis of their known clinical activity in a particular
disease site although none of them has been clearly superior.
For example, agents such as cisplatin, 5-fluorouracil, and car-
boplatin have been largely used in chemoradiation regimens.
Recently, the introduction of such new agents as gem-
citabine, vinorelbine, and taxanes for the treatment of
NSCLC has generated great interest in the identification of
more active and better tolerated combinations. In phase II
studies, the gemcitabine-cisplatin combination has exhib-
ited a favorable and safe profile.11-13 Gemcitabine (2=,2=-
difluoro-2=deoxycytosine) is a cytosine analog with a mod-
ification in the 2 position of the sugar ring. It is one of the
most extensively evaluated newer cytotoxic agents, charac-
terized by favorable toxicity profiles and better tolerated
than platinum-based regimens,14 with clinical activity in
solid tumors including NSCLC through a broad spectrum of
activity. Recent studies have demonstrated that by altering
deoxynucleoside triphosphate pools15-17 gemcitabine acts as
a potent radiosensitizer in several different solid tumor cell
lines in vitro—including lung cancer—at noncytotoxic con-
centrations. Although the mechanism of sensitization is not
yet clear, evidence suggests that gemcitabine lowers the
threshold for radiation-induced apoptosis.17 In an in vitro
study, Shewach and Lawrence15 demonstrated that short-
term (2-hour) exposure to gemcitabine was sufficient to
produce radiosensitization when cells were irradiated after
Abbreviations and Acronyms
CT  computed tomography
NSCLC non–small cell lung cancer
PD  progressive disease
PR  partial response
SD  stable disease24 or 48 hours, presumably because of the prolonged cellular
The Journal of Thoracieffects mediated by lengthy retention of the triphosphate form.
This suggests that once- or twice-weekly administration of
gemcitabine could effectively sensitize tumor cells during a
weekly course of radiotherapy. In a recent phase I and II
trial with induction carboplatin and gemcitabine followed
by concurrent chemoradiotherapy with vinorelbine and pac-
litaxel, followed by surgery, Argiris and colleagues18 re-
ported good results in terms of toxicity, objective response
to the treatment, and survival.
In a previous phase I controlled trial, we tested the use of
gemcitabine as radiosensitizer administered concurrently
with radiotherapy in the treatment of patients with unresect-
able locally advanced NSCLC, finding the maximum toler-
able dose to be 350 mg/m2 weekly for 5 weeks.19 On the
basis of this experience, we planned a prospective trial for
patients with unresectable stage IIIA and IIIB NSCLC of a
multiple modality therapy combining gemcitabine with con-
current radiation therapy and surgery. The objective of this
study was to assess this new treatment in terms of feasibility,
toxicity, tumor response, survival, and tumor recurrence.
Patients and Methods
This single-center, phase II, ongoing trial started in February 2001
at Policlinico Gemelli Hospital, Catholic University in Rome.
Patient accrual terminated in June 2003. The protocol was ap-
proved by the local institutional review committee. All patients
signed an informed consent form before being admitted to the
study.
Eligibility
Eligibility criteria included patients 18 to 75 years old with a
performance status of 0 or 1 on the Eastern Cooperative Oncology
Group scale. Patients also must have had pathologically or cyto-
logically confirmed locally advanced NSCLC judged inoperable or
unresectable (stage IIIa or IIIb), with no pulmonary or cardiovas-
cular contraindications to chemoradiotherapy and surgery. Other
required criteria were as follows: leukocyte count greater than
4000 cells/L, platelet count greater than 100,000 cells/L, he-
moglobin level greater than 10 g/dL, serum bilirubin level not
more than 1.5 times the upper limit of normal, serum alanine
aminotransferase and aspartate aminotransferase levels not more
than 2.5 times the upper limit of normal, normal creatinine level,
and creatinine clearance level greater than 60 mL/min. Exclusion
criteria included previous oncologic treatment and history of an-
other malignancy.
Diagnostic Procedures
Initial staging evaluation included patient history and physical
examination with evaluation of performance status, complete
blood cell count and hematochemical testing, electrocardiogram,
bronchoscopy, pulmonary function test, arterial blood gas analysis,
and perfusion nuclide scintigraphy. Chest radiography and com-
puted tomography (CT) of the chest, abdomen, and brain, as well
as bone scintigraphy, were performed to ensure the absence of
metastatic dissemination. NSCLC diagnosis was obtained by fine-
needle aspiration biopsy, endobronchial biopsy, or bronchoscopic
c and Cardiovascular Surgery ● Volume 131, Number 2 315
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mum diameter) mediastinal lymph nodes on CT scan was made by
cervical mediastinoscopy. All patients underwent surgical staging
with the Mountain revision of the international system for staging
lung cancer.2 Before the treatment plan was begun, a multidisci-
plinary team composed of thoracic surgeons, radiation oncologists,
pulmonologists, and medical radiologists evaluated all patients.
Treatment Regimen
Induction protocol. The treatment plan is summarized in Fig-
ure E1. Gemcitabine (350 mg/m2, or 300 mg/m2 for patients older
than 70 years) was administered weekly as a 30-minute intrave-
nous infusion at least 4 hours before radiation therapy. Concurrent
treatment with antiemetics, antibiotics, sedatives, cortisone, hema-
topoietic growth factors, and gastric protectors was permitted.
Radiotherapy was administered with an individualized ap-
proach according to the volume and location of the disease, with
the requirement that the 100% (5%) isodose should encompass
the entire target volume, with maximum dose to the spinal cord of
36 Gy. Gross tumor volume was the same as clinical target
volume, and planning target volume was clinical target volume
plus the surrounding 1.5-cm margin. Elective nodal irradiation was
never administered. The prescription dose was 50.4 Gy, adminis-
tered in daily single 1.8-Gy fractions or in 1.2-Gy doses twice
daily on weekdays. CT-based planning was performed in each
case. Heterogeneity corrections were applied. A photon beam with
6 to 10 MV energy was used in all cases.
A complete laboratory test with arterial blood gas analysis,
together with clinical, oncologic, and pneumologic examinations,
was carried out every week before the administration of gemcit-
abine. A control chest roentgenogram was taken when the dose of
20 to 25 Gy was reached.
In the case of hematologic grade 3 or nonhematologic grade 2
toxicity, the administration of gemcitabine was avoided. Radio-
therapy was discontinued if grade 4 hematologic or grade 3 non-
hematologic toxicity occurred. Treatment was eventually contin-
ued pending toxicity resolution; a maximum 7-day delay was
permitted. Any patient with declining performance status or rapid
progression of disease during treatment was removed from the
protocol.
Clinical response. Four weeks after induction chemoradio-
therapy was completed, patients underwent restaging to assess
clinical response. Restaging procedures included bronchoscopy,
pulmonary function tests, and CT scans of the chest and upper
abdomen.
Response to preoperative chemoradiation therapy was evalu-
ated by the multidisciplinary team according to response evalua-
tion criteria in solid tumors.11 Complete response was defined as
the total disappearance of all radiographic and clinical evidence of
disease. Partial response (PR) was defined as any response less
than complete but with greater than 30% reduction in the sum of
products of the crossed diameters of all measurable lesions. Pa-
tients with less tumor shrinkage were considered to have stable
disease (SD). Progressive disease (PD) was defined as a greater
than 20% increase in the sum of the products of the crossed
diameters of all measurable lesions or the appearance of new
locoregional or metastatic disease. The demonstration of meta-
static disease at any time was scored as PD, irrespective of any
316 The Journal of Thoracic and Cardiovascular Surgery ● Febrlocoregional improvement. Patients excluded from surgery received
multidrug chemotherapy and in selected cases boost irradiation.
Surgical procedure. All patients who at clinical evaluation had
a complete response, PR, or SD (given that the resectability criteria
had been met) underwent thoracotomy 1 to 2 weeks after restaging.
Mediastinoscopy was repeated in select cases. A lateral muscle-
sparing thoracotomy was used for all patients. The goal was to
remove the entire tumor area. Resection was considered complete
if proximal resection margins were free of tumor on frozen section
examination. Lobectomy was preferred when possible; however, a
bilobectomy or pneumonectomy was performed for primary tumor
invasion or regional lymph node metastases. When necessary,
resection of adjacent structures was performed. Unilateral medi-
astinal lymph node dissection was accomplished with all pulmo-
nary resections. In all patients who underwent resection, the bron-
chial stump was wrapped in an intercostal pedicled muscle flap.
Toxicity evaluation and feasibility. Adverse effects of induc-
tion treatment were recorded according to Common Toxicity Cri-
teria of National Cancer Institute of Canada, version 2.0. Feasibil-
ity was assessed by the ability of patients to complete induction
therapy, by operability, and by curative resectability (Cancer Ther-
apy Evaluation [http://ctep.cancer.gov/]. Maryland: National Can-
cer Institute, 1999. Common Toxicity Criteria, version 2.0 [Ac-
cessed 2004 May 24]. Available from: http://ctep.cancer.
gov/reporting/ctc.html).
Pathologic response. Tumor response was defined as down-
staging of cT or pN according to the indications of the American
Joint Committee on Cancer12: complete pathologic response was
defined as ypT0 N0, whereas partial pathologic response was
defined as reduction in either cT or pN without a reciprocal
increase in the other (PD).
Survival. Survival and tumor recurrence were assessed by
patient follow-up. Patients were to be followed up monthly for the
first 3 months, every 3 months for the next 2 years, every 6 months
for the next 3 years, and annually thereafter. Investigations in-
cluded interim history, physical examination, and laboratory tests.
Fiberoptic bronchoscopy and CT of the chest, abdomen, and brain
were carried out every 3 months for the first year, every 6 months
for the next 3 years, and yearly thereafter, or when clinical signs of
recurrence developed. Recurrence was classified as locoregional
(inside the ipsilateral thorax, excluding parenchymal nodules,
always classified as M), distant (outside the ipsilateral thorax),
or both.
Data Analysis
The survival probabilities were calculated with the Kaplan-Meier
method13 from the beginning of the induction treatment until
death, unavailability for follow-up, or time to evaluation for this
report and included patients with operative deaths (defined as
occurring within the same hospitalization as the operation or after
the initial discharge but related to the operation). Disease-free
survival was calculated from the first postoperative day until any
event such as tumor recurrence, incidence of second cancer, or
secondary condition. Statistical differences between the individual
curves were assessed with the log-rank test. The COX proportional
hazard model was applied for univariate and multivariate analysis
to confirm the prognostic effect of the factors on survival.
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Patient Characteristics
Between February 2001 and June 2003, a total of 46 patients
who met the aforementioned eligibility criteria entered into this
phase II trial. Clinical characteristics and staging are given in
Table 1. There were 41 patients with cIIIA disease and 5 with
cIIIB. Only 1 enrolled patient had N3 disease confirmed by
cervical mediastinoscopy—a small primitive neoplasm in-
volving the contralateral paratracheal nodes. Cervical me-
diastinoscopy was performed on all patients, with positive
results in 39 cases (84.8%). Thirty-seven patients (80.4%)
had ipsilateral mediastinal node involvement (N2 disease):
6 T1, 12 T2, 15 T3, and 4 T4. The last included 2 pulmonary
artery invasions and 1 each tracheal and superior vena cava
invasions. Clinical N1 stage was documented in 8 patients,
all with T3 tumor.
Induction Therapy
Thirty-eight of 46 patients undergoing this trial (82.6%)
received the full-dose induction treatment. During induction
therapy, most patients had moderate hematologic toxicity.
Only 4 patients required hospitalization: 3 for febrile neu-
tropenia and 1 for anemia necessitating blood transfusion.
Moderate nonhematologic toxicity (G1-G2) was seen in 15
patients (32.6%). In particular, nausea and vomiting were
TABLE 1. Patient characteristics (n  46)
Characteristic No. %
Age (y)
Median 64
Range 47-75
Sex
Male 37 80.4
Female 9 19.6
Eastern Cooperative Oncology
Group performance status
0 35 76.1
1 11 23.9
Histologic cell type
Squamous cell 24 52.1
Adenocarcinoma 18 39.1
Large cell 2 4.4
Adenosquamous 1 2.2
Other 1 2.2
Clinical and TNM staging
IIIA 41 89.1
T3 N1 8 17.4
T1 N2 6 13.0
T2 N2 12 26.1
T3 N2 15 32.6
IIIB 5 10.9
T4 N2 4 8.7
T1 N3 1 2.2seen in 14 patients (11 G1 and 3 G2), esophageal toxicity
The Journal of Thoraciwas limited to G1 in 5 cases and G2 in 1, and pneumonitis
was seen in 2 patients, 1 G1 and 1 G2. No patient had neuro-
toxicity or nephrotoxicity. There were no toxicity-related
deaths from induction therapy.
Five patients (4 cIIIA and 1 cIIIB) were not available for
restaging: 1 patient underwent surgery for abdominal aortic
aneurysm during the treatment, 3 refused to continue treat-
ment, and 1 died of treatment-unrelated causes. Thus a total
of 41 patients were available for restaging; of these, 38
patients (92.7%) received the full treatment.
No complete clinical responses were recorded. The over-
all clinical response rate (all PRs) among the patients with
restaged disease was 82.9% (initially 32 cIIIA and 2 cIIIB).
Five patients (12.2%, 4 cIIIA and 1 cIIIB) showed SD, and
2 patients (4.9%) had PD (initially 1 cIIIA and cIIIB).
No significant correlations were found among response
to treatment and clinical characteristics (age, sex, perfor-
mance status, TNM stage, and histologic type).
Surgery
Twenty-nine patients (28 with PR and 1 with SD, 27 cIIIA
and 2 cIIIB) from the restaged group (70.7%) who on
downstaging reentered the resectability criteria underwent
surgery. Of the remaining 12 patients (6 with PR, 4 with SD,
and 2 with PD), 4 refused surgery, 5 were judged to have
unresectable disease, and 3 were considered medically un-
able to undergo surgery. Radical resection was possible in
all the patients operated on and included lobectomy in 17
patients (58.6%), bilobectomy in 4 (13.8%), and pneumo-
nectomy in 8 (27.6%). Overall resectability rate (patients
undergoing resection among the entire enrolled population)
was 63%. Complex resections included 4 intrapericardial
pneumonectomies (13.8%) and 3 sleeve lobectomies (10.3%).
In most cases, some difficulties related to chemoradiotherapy-
induced fibrosis were encountered; nevertheless, a standard
major procedure was always performed. Thus the surgical
resectability rate (patients undergoing resection among all
patients considered appropriate candidates at restaging) was
100%.
No patient died within 30 days after the operation. Post-
operative morbidity was 13.8% (4/29) and included 1 pa-
tient with myocardial infarction, 1 with postpneumonec-
tomy empyema, 1 with prolonged air leak, and 1 with lobar
atelectasis necessitating twice-daily bronchoscopic aspira-
tion. Overall median postoperative hospitalization was 10
days (range 6-23 days).
Pathologic Response
Pathologic downstaging to stage 0 or I was observed in 18
patients (62% of the 29 undergoing resection, or 39% of the
total patient group of 46; Table 2). In particular, there were
5 patients (17.2%) who had no evidence of viable tumor
cells in the resected specimen (stage 0, initially 4 cIIIA and
c and Cardiovascular Surgery ● Volume 131, Number 2 317
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ypIA and 4 ypIB). Of interest, among the 9 patients with
downstaging to ypIA, 6 had only microscopic tumor cell
foci. Four patients (13.8%) had pathologic response to stage
II. Thus 22 of 29 patients (75.8%) responded to preoperative
treatment and had their disease downstaged. Three patients
(10.3%) showed a partial pathologic response, including 2
patients with downstaging from cT3 pN2 to ypT2 ypN2 and
1 patient with downstaging from cT3 pN2 to ypTmic (mi-
croscopic tumor remnants) ypN2. In 4 patients (13.8%),
pathologic staging corresponded to the clinical restaging
(SD). No pathologic upstaging was observed in the group
undergoing operation.
Survival
Median follow-up was 13 months (range 2-28 months) and
was complete for all patients. Median overall survival was
13 months. The calculated 1- and 2-year Kaplan-Meier
survivals among all 46 patients were 75% and 66.1%,
respectively (Figure E2). When patients were compared
according to resection, the median survival and the 1- and
2-year projected survivals were 19 months, 92.8%, and
81.8%, respectively, for the operative group of 29 and 5
months, 42.5%, and 36.1%, respectively, for patients who
did not undergo operation (n  17, P  .0002; Figure E3).
In the resection group, 25 patients (86.2%) were alive at 2
years, with a median disease-free survival of 16 months
(Figure E4.) Among the 29 who underwent resection, re-
currence developed in 4 (1 local and 3 distant metastases)
and was the cause of death in 3 cases. The fourth patient
died of cancer-unrelated causes.
Discussion
Surgery, when possible with radical intent, is the only
chance of cure for patients with lung cancer. Good results
are obtained with surgery alone in only a few select cases
when the disease is diagnosed to be at stage III. The vast
majority of patients with stage III NSCLC do not benefit
from surgery alone, even when the surgical approach with
TABLE 2. Clinical and pathologic downstaging among pa-
tients who underwent operation
Stage cIIIA Stage cIIIB Total
Pathologic staging No. % No. % No. %
0 4 13.8 1 3.4 5 17.2
IA 9 31.1 9 31.1
IB 4 13.8 4 13.8
IIA 2 6.9 2 6.9
IIB 2 6.9 2 6.9
IIIA 7 24.1 7 24.1
Total 28 96.6 1 3.4 29 100radical intent is technically feasible. Moreover, patients in
318 The Journal of Thoracic and Cardiovascular Surgery ● Febrthis very same class do not benefit either from any thera-
peutic strategy relying on a single kind of treatment,
whether radiotherapy or chemotherapy. In the last two de-
cades, impressive steps forward have been taken in the
integration of different treatment modalities in an effort to
offer a reasonable chance of cure for this complex disease.
To date, the most frequently adopted treatment strategy
for locally advanced NSCLC is concurrent radiochemo-
therapy.4 In very recent years, the discussion has focused on
two main points: the eventual induction potential of con-
current radiochemotherapy regimens (demonstrated to be
more effective than those of chemotherapy only)5,9,20,21 and
the value and role of surgery within this setting.4,22
An authoritative experience4,22 has demonstrated that pa-
tients who have been operated on after radiochemotherapy
treatment have better results in terms of progression-free
survival (median 14 vs 11.7 months, 3 years 29% vs 19%).
These results have led to a multicenter, randomized, phase
III trial (new Intergroup Trial R0333/S0332) in which the
radiochemotherapy plus surgery arm is matched with an
arm of chemotherapy plus surgery, thus demonstrating a
codified role and a solid value of surgery.4,22
In the complex clinical environment, as is the case with
locally advanced NSCLC, in terms of extreme simplifica-
tion, we can say that the ideal induction treatment is feasi-
ble, safe, and effective, with a negligible impact on surgical
morbidity and mortality. The feasibility, safety, and efficacy
of induction concurrent radiochemotherapy have been in-
vestigated extensively.5,20 Frequently, the analysis of patho-
logic downstaging rate has been used as a surrogate end
point in respect to survival.23-25
In our personal experience, we have investigated the
feasibility and safety of the association of radiotherapy and
gemcitabine in a previously reported phase I trial.19 In that
experience, we demonstrated that concurrent radiochemo-
therapy treatment with weekly administered gemcitabine
(maximum tolerable dose 350 mg/m2) plus involved field
radiotherapy at the dose of 50.4 Gy was safe and feasible
and produced an interesting pathologic downstaging rate in
those cases in which, on the basis of favorable clinical
response, surgical operation had been incidentally indicated.
On the basis of those results, we planned the phase II trial
reported in this article.
It is important to highlight the data regarding toxicity,
surgical morbidity and mortality, and pathologic downstag-
ing. The treatment has been well tolerated, with a high
patient compliance rate (87.7%). Even though hematologic
toxicity was to be expected in the low range, the esophageal
and pulmonary toxicity was within low rates relative to
similar treatments.26 This can be explained by the fact that
the adopted radiotherapy volumes were focused on the
macroscopic disease with a total dose of 50.4 Gy (useful for
induction approaches but lower than that adopted for radical
uary 2006
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therapy planning.
With regard to surgical morbidity and mortality, despite
the fact that it is a generally accepted idea that complication
rates could be higher among those patients who are operated
on after induction therapy, to date several methodologic
differences have biased the interpretation of the reported
results. Different kinds of treatment such as induction ther-
apy (chemotherapy only vs radiochemotherapy), different
chemotherapeutic agents and schedules, different radiother-
apy techniques and schedules, different staging and restag-
ing procedures, and different surgical indication criteria and
timing as well as different surgical approaches all render the
vast amounts of available data absolutely inhomogeneous.
Moreover, and significantly because the most significant
expected surgery-related morbidity is pulmonary, func-
tional data and evaluation of pulmonary function at the
different stages of any multimodality therapy approach
have seldom been reported.27 In any case, it is clear that
when a pneumonectomy is necessary, the morbidity and
mortality correlated with this kind of operation are signifi-
cantly higher if induction therapy has been administered
preoperatively.22,23,28
In our experience, surgical morbidity and mortality were
within the permitted ranges. This can be explained by the fact
that the pneumonectomy rate was low because the extent of
operation had been modulated according to the restaged
morphologic type of the disease with intraoperative check
of surgical radicality. In our opinion, this gives the best
value to the downstaging obtained with induction therapy.
We retrospectively reviewed the pre–induction therapy clin-
ical data and estimated that 16 of the patients operated
(55.1%) would actually probably have required a pneumo-
nectomy at presentation, mainly because of central airway
involvement (5 patients), bulky hilar nodal disease (10
patients), and vascular involvement (1 patient).
The pathologic downstaging rate to stage 0 or I (18/46,
39.2%) is similar to that reported by others5,22,29,30 (12.5%-
33.7%) and confirms that gemcitabine, even if used at
noncytotoxic levels as a single chemotherapeutic agent, is a
powerful radioenhancer essentially because a favorable
pharmacokinetic characteristic of this drug is the retention
of its cytotoxic metabolite within cells, with terminal elim-
ination rates as long as 72 hours. This allows a single shot
of gemcitabine to cover more than one radiotherapy appli-
cation (as many as six in hyperfractionated schedules).
It has been demonstrated that pathologic downstaging in
induction therapy trials is directly and significantly corre-
lated with long-term survival,25 and our recent experience5
confirmed this evidence. The data regarding a positive long-
term overall survival trend obtained in this phase II trial in
patients with resected disease (81.8% at 2 years) should be
considered cautiously in light of the short follow-up range;
The Journal of Thoracihowever, they strengthen the value of pathologic downstag-
ing itself as an effective surrogate end point for the evalu-
ation of any induction therapy protocol efficacy.
In light of the reported experiences, we conclude that
induction therapy with gemcitabine and radiotherapy for
locally advanced NSCLC is feasible, safe, and effective. It
does not impair surgical morbidity and mortality. The ob-
tained rate of pathologic downstaging was reasonably high
and was associated with a good long-term survival trend.
However, further investigation is encouraged in proper con-
trolled, randomized, phase III trials.
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Discussion
Dr Ross M. Bremner (Los Angeles, Calif). Galetta and colleagues
are to be congratulated on an excellent presentation and for per-
320 The Journal of Thoracic and Cardiovascular Surgery ● Febrforming a well-designed single-institution study. The article is also
well written and thoughtful. This group has used a combination of
a radiosensitizing drug, gemcitabine, at low dose with concurrent
radiotherapy in a neoadjuvant setting in an attempt to improve the
survival results of patients with this difficult stage III NSCLC. This
is a phase II study, and an interim analysis at that, and we should
keep that in mind in our interpretation of the results. The surgical
results are impressive, with no deaths and low morbidity, although
1 postpneumonectomy empyema may have been related to a
bronchial stump complication. The 2-year survival among the
resection group is also impressive, although caution should be
exercised when interpreting the comparison between the survival
of patients who underwent resection and those who did not. These
are two very different populations and probably represent different
tumor biologic characteristics. In fact, I think that these groups
should probably not be compared. Most of the patients with
unresected disease were medically unfit for surgery or had pro-
gression of disease on induction therapy, obviously constituting a
group with a worse prognosis. Nonetheless the early results of
those patients who underwent resection do appear promising and
warrant further study. The pathologic response rates are also
impressive. These results may in part be related to the sensitizing
effect of gemcitabine but are also probably related to the confor-
mal approach of radiotherapy. This 3-dimensional approach has
altered the radiation therapist’s ability to focus higher doses of
radiation to more precisely defined fields with lessening of side
effects to surrounding tissue, and I think the results of radiotherapy
today are different from those of a decade ago, as the literature is
beginning to attest. This approach with low-dose gemcitabine
combined with radiotherapy is really designed at improving local
control, and it appears to be effective in that. The gemcitabine was
too low a dose to have a significant systemic effect. I was inter-
ested to note that most patients had squamous cell carcinoma,
which is more frequently a local problem than either adenocarci-
noma or large cell cancer. In many countries, America included,
the overwhelming majority of NSCLCs now are adenocarcinomas,
and I think we all subscribe to the paradigm that N2 disease should
be considered systemic disease, even if not apparent on our current
imaging modalities. To this end, perhaps there is greater value to
neoadjuvant chemotherapy with systemic cytotoxic doses before
addressing local disease with radiotherapy and surgery.
I have two questions, Dr Galetta. First, among the recurrences
seen in your series, how many of them were adenocarcinoma, and
where were the sites of the recurrence? Second, there is no mention
in the article of adjuvant treatment in these patients. Were any
treated with postoperative chemotherapy? If not, will you change
your practice in light of the recent data, some from your country,
that suggest a benefit of chemotherapy for this group of patients
undergoing resection?
Dr Cesario. Dr Bremner, thank you very much for your com-
ments and questions. Regarding the first question, we had 4 recur-
rences. Three were distant, and 1 was local. Distant recurrences
were all in patients with adenocarcinoma and all at the level of the
brain.
Regarding your second question, this was a trial that was
designed before the International Adjuvant Lung Cancer Trial
(IALT) results and before Adjuvant Lung Cancer Project Italy
(ALPI) which was the study made in my country regarding adju-
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on the basis of pathologic staging. No adjuvant chemotherapy was
administered for pathological stage I but it was given for patho-
logical stage II and III. In highly selected cases, boost radiation
therapy was given.
Dr Robert J. Cerfolio (Birmingham, Ala). That was excellent
work. We appreciate you bringing the interim analysis to us; it is
helpful. I have a few questions. First, you didn’t mention your
policy or general belief about restaging and surgical selection. Do
you believe that recalcitrant N2 disease—according to repeated
mediastinoscopy, repeated endoscopic ultrasonography with fine-
needle aspiration, or even thoracotomy with frozen section—is a
contraindication to resection? If results are positive, are there any
patients for whom you still resect?
Dr Cesario. We have discussed the matter of remediastinos-
copy in a recent paper published during the last year, and we do not
believe that remediastinoscopy can be of any help in N2 cases. It
can be of help in N3 cases, but in our experience with remedias-
tinoscopy, all the operations were performed by the same senior
surgeon who did the first mediastinoscopy. He encountered several
difficulties in performing the operation, and once he reached the
area of biopsy and of rebiopsy, he was not certain to have resa-
mpled the same area. When we sent frozen sections, the patholo-
gist was saying we were crazy if we wanted a diagnosis on that
tissue. So remediastinoscopy is quite a difficult issue in our opin-
ion.
Dr Cerfolio. Do you operate if there is recalcitrant N2 disease,
then?
Dr Cesario. Just on CT scan evidence.
Dr Cerfolio. So you don’t use tissue confirmation. My second
question concerns bronchial buttressing. I assume you are using an
intercostal muscle flap harvested before chest retraction or a ser-
ratus. Do you use these? My final question concerns the use of a
60-Gy dose before the operation rather than a 45-Gy dose. We
have come to prefer a higher, curative dose, because if after
restaging patients still have N2-positive disease and surgery is
denied, they do not have a large gap in the completion of their
“curative dose” of radiotherapy, which would hinder its efficacy.
We have also done resections in more than 75 patients after 60-Gy
radiotherapy, and we find the operation and postoperative compli-
cations no different. Do you have any comments on this strategy,
or any experience in pulmonary resection after 60-Gy therapy?
Dr Cesario. Your question was about protection of the bron-
chial stump?
Dr Cerfolio. Right.
Dr Cesario. Yes. Not 60 Gy but 50 Gy.
The Journal of ThoraciDr Cerfolio. Have you operated after 60 Gy?
Dr Cesario. No, no, 50.4 Gy.
Dr Cerfolio. I understand that for this series, but what about in
other cases?
Dr Cesario. Every patient had the bronchial stump protected
by intercostal muscle flap.
Dr Douglas Wood (Seattle, Wash). I have two brief questions.
First, were you doing mediastinoscopy on every patient, so that
these are all mediastinoscopy-proven IIIA disease, or was this
predominantly based on radiologic staging? Second, regarding the
extent of resection; were these all R0 resections? You did not
mention whether you had any R1 or R2 resections.
Dr Cesario. To your first question, we did mediastinoscopy in
all cases in which the CT scan led us to suspect mediastinal
involvement, so all patients with clinical N2 disease underwent
mediastinoscopy.
To your second question, yes, we had all R0 resection. To
maximize the effect of the induction treatment, we check the
resection intraoperatively for completeness in an organ-sparing
attitude. This is intended to give the maximum strength to the
effect of the chemotherapy. In a T4 case, for example a big tumor
invading the pulmonary artery, if you have a good response so that
you can do a lobectomy rather than a pneumonectomy, we find that
this is the correct way, but intraoperatively you have to check
whether resection is complete.
Dr Wood. Well, it’s impressive to have all R0 resections in this
kind of series, so I congratulate you. Finally, what is the perceived
purpose or benefit of this regimen? Are you trying to decrease
toxicity or improve outcomes relative to standard therapy with
cisplatin-based combination chemoradiotherapy? Are you trying to
make it so that every patient can get through it more easily, or do
you think it will actually result in better outcomes?
Dr Cesario. Thank you for this question, because it provides an
occasion for me to explain what we are doing now. We were trying
to find a good local treatment for patients with bad local disease.
What we are doing now for patients with T4 stage IIIB disease is
to give them systemic chemotherapy, three cycles of full-dose
chemotherapy, and then restage. If we find that they have a
response, we can give them this kind of local treatment. Coming
after systemic chemotherapy at full doses, it should be less toxic.
This is what we are doing now. Our aim was to find a local
treatment that was both effective and less toxic to be given after
systemic chemotherapy at full dosage in a complex multimodality
three-stage treatment: chemotherapy, induction radiochemother-
apy, and then, if possible, surgery.
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